



2018 APASL Single Topic Conference on Hepatitis B Virus Taipei


HBV

APASL STC 2018

Towards Hepatitis B Elimination - Following Hepatitis C Cure

June 22-24

Taipei International Convention Center
Taipei, Taiwan



Chau-Ting Yeh

CURRENT POSITIONS

Director, Liver Research Centre, Chang Gung Memorial Hospital, Linkou, Taiwan

EDUCATIONAL AND CAREER EXPERIENCES

- 1977-1984 National Taiwan University, Medical School, M.D.
- 1988-1992 Dept. of Molecular Microbiology and Immunology, University of Southern California, Ph.D.
- 2001-2002 Director, Division of Hepatology, Dept. of GI, Chang Gung Memorial Hospital
- 2002-2004 Adjunct Investigator, Dept. of Biotechnology and Pharmaceutical Research, NHRI
- 2002-now Professor, Department of Internal Medicine; Chang Gung University
- 1993-now Attending Doctor, Dept. of GI, Chang Gung Memorial Hospital
- 2007-now Director, Liver Research Center, Chang Gung Memorial Hospital

PUBLICATION/ AWARDS AND HONORS/ OWNED PATENTS

Honors and Awards:

- Professional Award, USC graduate school; 1990
- Professor Song JL's Research Award; 1996
- National Science Council Type-A Award; 1998, 1999, 2000
- National Science Council Assisted Special Talent Award in University 2012

Patents (after 2012)

- US Patent # 8759096 Microfluidic chip and method using the same (2014-6-24)
- US Patent # 8709720 Methods and kits for predicting the responsiveness of HCC patients to 5FU based chemotherapy (2014-4-29)
- US Patent # 9163290 Methods for detecting hepatitis B virus surface gene non-sense mutations (2015-10-20)
- US Patent #9839672 Treatment of thrombocytopenia using orally administered interferon (2017-12-12)

Selected publications (First or Correspondence):

- 1: Yeh CT, et al. Cell cycle regulation of nuclear localization of hepatitis B virus core protein. *PNAS*. 1993;90(14):6459-63.
- 2: Yeh CT, et al. Prednisolone modulates the therapeutic effect of interferon to eliminate preferentially the hepatitis B virus precore stop mutant. *J Hepatol*. 2000;32(5):829-36.
- 3: Yeh CT, et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. *Hepatology*. 2000;31(6):1318-26.



2018 APASL Single Topic Conference on Hepatitis B Virus Taipei

HBV

APASL STC 2018

Towards Hepatitis B Elimination - Following Hepatitis C Cure

June 22-24

Taipei International Convention Center
Taipei, Taiwan



- 4: Hsu CW, Yeh CT*, et al. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. *Gastroenterology*. 2007;132(2):543-50.
- 5: Yeh CT, et al. Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. *Hepatology*. 2010;52(6):1922-33.
- 6: Hsu CW, Yeh CT*. Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy. *Hepatology*. 2011;54(1):101-8.
- 7: Lai MW//Yeh CT*. Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination. *Gastroenterology*. 2012;143(2):400-7.
- 8: Liao CH, Yeh CT (co-first author), et al. Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells. *Hepatology*. 2012;55(3):910-20.